Edition:
United States

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

64.05EUR
15 Dec 2017
Change (% chg)

€-0.01 (-0.02%)
Prev Close
€64.06
Open
€63.71
Day's High
€64.11
Day's Low
€63.02
Volume
830,803
Avg. Vol
352,648
52-wk High
€79.05
52-wk Low
€56.50

Latest Key Developments (Source: Significant Developments)

UCB Bimekizumab Announces Results For Phase 2b Of BE Agile Study ‍​
Thursday, 14 Dec 2017 01:16am EST 

Dec 14 (Reuters) - UCB SA ::BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS‍​.POSITIVE FIRST RESULTS IN ANKYLOSING SPONDYLITIS FROM PHASE 2B BE AGILE STUDY OF BIMEKIZUMAB SHOW STATISTICAL SIGNIFICANCE IN MULTIPLE DOSE GROUPS.BIMEKIZUMAB WAS GENERALLY WELL TOLERATED AND NO UNEXPECTED SAFETY SIGNALS WERE OBSERVED.THE STUDY ACHIEVED THE PRIMARY ENDPOINT (ASAS40)‍​.RESULTS FROM THIRD PHASE 2B STUDY OF BIMEKIZUMAB IN PSORIATIC ARTHRITIS EXPECTED SOON.UP TO 47% OF PATIENTS ACHIEVE AT LEAST 40% IMPROVEMENT VERSUS 13% OF PATIENTS RECEIVING PLACEBO, AT WEEK 12 ‍​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

UCB 9-month revenue up at 3.3 billion euros, 2017 outlook increased
Friday, 20 Oct 2017 01:21am EDT 

Oct 20 (Reuters) - UCB SA ::9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION .9-MONTH NEUPRO REVENUE EUR 230 MILLION VERSUS EUR 217 MILLION YEAR AGO‍​.9M VIMPAT REVENUE EUR 707‍​ MILLION VERSUS EUR 586 MILLION YEAR AGO.9M KEPPRA REVENUE EUR 607‍​ MILLION VERSUS EUR 538 MILLION YEAR AGO.9M IMMUNOLOGY/CIMZIA REVENUE EUR ‍​1.02 BILLION VERSUS EUR 927 MILLION YEAR AGO.9-MONTH NEUPRO REVENUE EUR 230 MILLION VERSUS EUR 217 MILLION YEAR AGO.9-MONTH BRIVIACT REVENUE EUR 57 MILLION VERSUS EUR 11 MILLION YEAR AGO.FINANCIAL OUTLOOK 2017 INCREASED: NOW REVENUE EXPECTED BETWEEN €4.4 - 4.5BN. REBITDA BETWEEN €1.25 - 1.35BN‍​.9M NEUROLOGY REVENUE EUR ‍​ 1.60 BILLION VERSUS EUR 1.35 BILLION YEAR AGO.FINANCIAL OUTLOOK 2017 INCREASED: NOW EXPECTED CORE EPS BETWEEN €4.10 – 4.50.BRIVIACT APPROVED AS MONOTHERAPY IN THE U.S.‍​.VIMPAT APPROVED AS MONOTHERAPY IN JAPAN AND FOR CHILDREN AS ADD-ON THERAPY IN THE EU. ‍​.  Full Article

‍Partners Connected Health and UCB announce epilepsy partnership​
Wednesday, 11 Oct 2017 10:45am EDT 

Oct 11 (Reuters) - UCB SA ::‍PARTNERS CONNECTED HEALTH AND UCB ANNOUNCE COLLABORATION TO DEVELOP HEALTHCARE SOLUTIONS TO SUPPORT PEOPLE LIVING WITH EPILEPSY​.  Full Article

UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use
Thursday, 21 Sep 2017 01:31pm EDT 

Sept 21 (Reuters) - UCB SA : :ANTI-EPILEPTIC DRUG VIMPAT (LACOSAMIDE) RECEIVES EU APPROVAL FOR PAEDIATRIC USE.VIMPAT APPROVED FOR MONOTHERAPY AND ADJUNCTIVE THERAPY OF PARTIAL-ONSET (FOCAL) SEIZURES IN CHILDREN AGED 4 YEARS AND OLDER.  Full Article

UCB H1 net sales up at EUR 2.04 billion; increases FY 2017 outlook
Thursday, 27 Jul 2017 01:04am EDT 

July 27 (Reuters) - UCB SA : :H1 REBITDA EUR 742 MILLION VERSUS EUR 549 MILLION YEAR AGO.H1 NET SALES EUR 2.04 BILLION VERSUS EUR 1.85 BILLION YEAR AGO.H1 GROSS PROFIT INCREASED TO € 1.67 BILLION (+17%, +15% CER).FOR FY17, REVENUE ARE NOW EXPECTED TO REACH € 4.35 - 4.45 BILLION, RECURRING EBITDA SHOULD INCREASE TO € 1.15 – 1.25 BILLION.FOR FY17, CORE EARNINGS PER SHARE ARE EXPECTED IN THE RANGE OF € 3.70 – 4.15 BASED ON AN EXPECTED AVERAGE OF 188 MILLION SHARES OUTSTANDING.  Full Article

UCB and Dermira announce US and EU regulatory submissions for Cimzia
Tuesday, 25 Jul 2017 01:15am EDT 

July 25 (Reuters) - UCB SA ::UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS.  Full Article

UCB anti-epileptic drug Vimpat receives EU CHMP positive opinion
Monday, 24 Jul 2017 01:34am EDT 

July 24 (Reuters) - UCB SA ::ANTI-EPILEPTIC DRUG VIMPAT RECEIVES EU CHMP POSITIVE OPINION FOR BOTH MONOTHERAPY AND ADJUNCTIVE THERAPY IN CHILDREN AGED 4 YEARS AND OLDER WITH EPILEPSY.EUROPEAN COMMISSION APPROVAL DECISION IS EXPECTED IN Q3 2017.  Full Article

UCB Q1 Cimzia sales up at 317 million euros
Monday, 24 Apr 2017 01:41am EDT 

April 24 (Reuters) - UCB SA ::Q1 immunology/Cimzia sales 317 million euros ($344 million) versus 281 million euros year ago.Q1 Vimpat sales 239 million euros versus 188 million euros year ago.Q1 Neupro sales 73 million euros versus 71 million euros year ago.Q1 Keppra sales 210 million euros versus 168 million euros year ago.Q1 revenue 1.124 million euros versus 974 million euros year ago.Expects 2017 revenue to reach 4.25 - 4.35 billion euros .Expects 2017 recurring EBITDA increase to 1.15 - 1.20 billion euros .Core earnings per share are expected in the range of 3.70 – 4.00 euros based on an expected average of 188 million shares outstanding.  Full Article

UCB and Q-State enter into multi-yr therapeutics discovery collaboration
Tuesday, 4 Apr 2017 01:09am EDT 

UCB SA : And Q-state biosciences form research collaboration to develop novel therapeutics for genetic subtypes of epilepsy . Financial terms are not being disclosed, nor are the genetic targets that are the subject of the research .Program includes research support, as well as prospective preclinical and clinical milestones and royalties.  Full Article

BRIEF-UCB Bimekizumab Announces Results For Phase 2b Of BE Agile Study ‍​

* BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS‍​